Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) Debt-to-Revenue : 0.59 (As of Jun. 2024)

Nanjing King-Friend Biochemical Pharmaceutical Co Debt-to-Revenue Chart

Nanjing King-Friend Biochemical Pharmaceutical Co Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Debt-to-Revenue		Get a 7-Day Free Trial					0.55	1.12	0.56	0.80	0.66

Nanjing King-Friend Biochemical Pharmaceutical Co Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Debt-to-Revenue	Get a 7-Day Free Trial															0.82	0.98	0.82	0.68	0.59

Competitive Comparison of Nanjing King-Friend Biochemical Pharmaceutical Co's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Nanjing King-Friend Biochemical Pharmaceutical Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nanjing King-Friend Biochemical Pharmaceutical Co's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nanjing King-Friend Biochemical Pharmaceutical Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Nanjing King-Friend Biochemical Pharmaceutical Co's Debt-to-Revenue falls into.

Nanjing King-Friend Biochemical Pharmaceutical Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Nanjing King-Friend Biochemical Pharmaceutical Co's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Nanjing King-Friend Biochemical Pharmaceutical Co's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Jun. 2024) Revenue data.

Nanjing King-Friend Biochemical Pharmaceutical Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Nanjing King-Friend Biochemical Pharmaceutical Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanjing King-Friend Biochemical Pharmaceutical Co Business Description